重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床效果  

Clinical effect of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of acute heart failure

作　　者：李媛妮 白壹鹏 赵文鸽 LI Yuanni;BAI Yipeng;ZHAO Wenge(General Hospital of Pingmei Shenma Group,Pingdingshan 467000,China)

机构地区：[1]平煤神马集团总医院,河南平顶山467000

出　　处：《临床医学研究与实践》2022年第19期59-61,共3页Clinical Research and Practice

摘　　要：目的探讨重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床效果。方法将2020年2月至2021年2月我院收治的96例急性心力衰竭患者随机分为对照组(48例,重组人脑利钠肽)和研究组(48例,重组人脑利钠肽联合左西孟旦)。比较两组的临床效果。结果治疗后,两组的N末端B型利钠肽原(NT-proBNP)、去甲肾上腺素(NE)、半乳糖凝集素3(Gal-3)、肽素(CPP)水平均降低,且研究组低于对照组(P<0.05)。治疗后,两组的白细胞介素-6(IL-6)、同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)水平均降低,且研究组低于对照组(P<0.05)。治疗后,两组的游离甲状腺素(FT_(4))、乳酸(LA)水平均降低,总三碘甲状腺原氨酸(TT_(3))水平升高,且研究组优于对照组(P<0.05)。两组不良反应总发生率无明显差异(P>0.05)。结论重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的效果显著,有利于改善患者神经内分泌状态,调节血清相关指标水平,且不会显著增加不良反应。Objective To investigate the clinical effect of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of acute heart failure. Methods A total of 96 patients with acute heart failure treated in our hospital from February 2020 to February 2021 were randomly divided into control group(48 cases, recombinant human brain natriuretic peptide) and study group(48 cases, recombinant human brain natriuretic peptide combined with levosimendan). The clinical effects of the two groups were compared. Results After treatment, the levels of N-terminal proB-type natriuretic peptide(NT-proBNP), noradrenaline(NE), galectin-3(Gal-3) and copeptin(CPP) in the two groups decreased, and those in the study group were lower than the control group(P <0.05). After treatment, the levels of interleukin-6(IL-6), homocysteine(Hcy) and hypersensitive C-reactive protein(hs-CRP) in the two groups decreased, and those in the study group were lower than the control group(P<0.05). After treatment, the levels of free thyroxine(FT_(4)) and lactic acid(LA) in the two groups decreased, the level of total triiodothyronine(TT_(3)) increased, and those in the study group were better than the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Recombinant human brain natriuretic peptide combined with levosimendan in the treatment of acute heart failure has a significant effect. It is helpful to improve neuroendocrine status of patients,regulate serum related indicators and without significant increase in adverse reactions.

关 键 词：急性心力衰竭 重组人脑利钠肽 左西孟旦 

分 类 号：R541.6[医药卫生—心血管疾病]